Company Filing History:
Years Active: 1992-1993
Title: Cornelus G Janssen: Innovator in Antipsychotic Treatments
Introduction
Cornelus G Janssen is a notable inventor based in Vosselaar, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antipsychotic medications. With a total of 2 patents, his work has had a meaningful impact on the treatment of psychotic diseases in warm-blooded animals.
Latest Patents
Janssen's latest patents include innovative compounds such as 3-piperidinyl-1,2-benzisoxazoles. The first patent relates to C.sub.2-20 alkanoic acid esters of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6, 7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, along with its pharmaceutically acceptable acid addition salts and enantiomeric forms. This invention is particularly useful in treating warm-blooded animals suffering from psychotic diseases. The second patent focuses on novel 3-piperidinyl-1,2-benzisoxazoles that exhibit long-acting antipsychotic properties, also aimed at treating psychotic conditions in warm-blooded animals.
Career Highlights
Cornelus G Janssen is associated with Janssen Pharmaceutica NV, a prominent company in the pharmaceutical industry. His work at this organization has allowed him to contribute to groundbreaking research and development in the field of mental health treatments.
Collaborations
Janssen has collaborated with notable colleagues such as Alfonsus G Knaeps and Ludo E Kennis. These partnerships have facilitated the advancement of innovative solutions in the pharmaceutical sector.
Conclusion
Cornelus G Janssen's contributions to the field of pharmaceuticals, particularly in antipsychotic treatments, highlight his role as an influential inventor. His patents reflect a commitment to improving the health and well-being of warm-blooded animals suffering from psychotic diseases.